What is Supernus Pharmaceuticals's estimated fair value?

Supernus Pharmaceuticals (SUPN) reported estimated fair value of $199.37M in Q1 2026.

How has Supernus Pharmaceuticals's estimated fair value changed year-over-year?

Supernus Pharmaceuticals's estimated fair value decreased by 42.7% year-over-year, from $347.74M to $199.37M.

What is the long-term trend for Supernus Pharmaceuticals's estimated fair value?

Over 4 years (2021 to 2025), Supernus Pharmaceuticals's estimated fair value has grown at a -8.3% compound annual growth rate (CAGR), from $255.41M to $180.22M.

Supernus Pharmaceuticals SUPN Estimated Fair Value

Estimated Fair Value at other companies

JPMorgan ChaseJPM

$549.04B+37.5%

3MMMM

$431M-39.6%

KKR & Co.KKR

$87.11B+10.8%

Bank of AmericaBAC

$368.96B-1.9%

Fifth Third BankFITB

$46.16B+16.1%

PNC Financial ServicesPNC

$71.07B+12.2%

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.62B+62.8%

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's estimated fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's estimated fair value?: Supernus Pharmaceuticals (SUPN) reported estimated fair value of $199.37M in Q1 2026.
How has Supernus Pharmaceuticals's estimated fair value changed year-over-year?: Supernus Pharmaceuticals's estimated fair value decreased by 42.7% year-over-year, from $347.74M to $199.37M.
What is the long-term trend for Supernus Pharmaceuticals's estimated fair value?: Over 4 years (2021 to 2025), Supernus Pharmaceuticals's estimated fair value has grown at a -8.3% compound annual growth rate (CAGR), from $255.41M to $180.22M.